Role of Epigenetics in Cancer and Targeted Therapies for Oncologic Treatments
Martha Srinivas
*
Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.
Salunkhe Pratiksha Sanjay
Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.
Londhe Pratima Manik
Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.
Vishal Bharat Babar
Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.
Koppula Maheshwari
Department of Pharmaceutics, Joginpally B.R Pharmacy College, Yenkapally (V), Moinabad(M), Telangana, JNTU, Hyderabad-500075, India.
*Author to whom correspondence should be addressed.
Abstract
DNA sequence has little bearing on the dynamic and heritable changes to the genome that occur in epigenetics. Both genetic and epigenetic alterations influence the development of cancer. There are several opportunities for therapeutic interventions because epigenetic modifications can be reversed. Many epigenetic drugs are currently used globally to treat conditions including leukemia and myelodysplastic syndrome. Owing to their malleability and vulnerability to outside factors, epigenetic modifiers are becoming intriguing targets for a number of cancer treatments. Recently, a large number of epi-drugs have been developed, and they may find application in clinical situations. The aforementioned initiatives to realize the potential of epigenetic medicines for efficient cancer treatment are summed up in this review. The maintenance of cell identity and the spatial and temporal regulation of gene expression depend on the proper coordination of epigenetic regulators. Both genetic and epigenetic changes contribute to cancer. The development of medications that target epigenetic regulators has advanced significantly over the past few decades, with numerous medications currently under assessment in research studies. In how they could be used to treat cancer. We also go over the preclinical and clinical outcomes of epigenetic medication combination therapies as well as other therapies including immune-based and targeted medicines.
Keywords: Heritable modifications, leukemia, myelodysplastic syndrome, epigenetic modifiers, epi-drugs, Malleability